Mind Medicine

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).

Mind Medicine (MindMed) Inc. - Common Shares

Mind Medicine Inc

Press Releases

MindMed to Present at the 2025 RBC Capital Markets Global Healthcare Conference

MindMed Announces New Employee Inducement Grants

MindMed Strengthens Executive Team with Appointment of Brandi Roberts, CPA, as Chief Financial Officer

MindMed to Participate in June Investor Conferences

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025

MindMed Reports Q2 2025 Financial Results and Business Updates

ATAI

CMPS

CYBN

MNMD

SAGE

Oppenheimer

Chardan Capital

Baird

HC Wainwright & Co.

Evercore ISI Group

MiniMed

Comments

Mind Medicine

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO